Company intelligence / Profile preview

Narrow River Management

New York, New York, United Statesprweb.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Narrow River Management focuses on developing therapies for unmet medical needs, particularly in renal diseases. It has formed companies like River Vision Development Corp., which developed teprotumumab (Tepezza) for Thyroid Eye Disease.

Therapeutic areas: EndocrinologyNephrology
Modalities: Small moleculespossibly monoclonal antibodies (mAbs) through its portfolio companies
Industry: Biotech

Drug pipeline

1 asset

teprotumumab

Commercial

Indications: Thyroid Eye Disease

Partnerships

SR OneBain Capital Life SciencesHBM Healthcare InvestmentsPureos Bioventures

Beyond the preview

Go deeper on Narrow River Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Narrow River Management.

Explore the full profile